Stock Comparison
PAVM vs PFE
PAVmed Inc vs Pfizer Inc
Who's the better investment? Let's break it down.
The Verdict
PFE takes this one.
PFE edges out the competition with a 2.2-point advantage. Not a blowout, but the numbers favor PFE.
Want to compare any two stocks?
Sign up free — get 3 DVR analyses/day, 1800+ stocks, portfolio roast. No credit card.
Valuation
PAVM
Metric
PFE
Market Cap
P/E Ratio
Lower may indicate better value
Forward P/E
Price/Book
EV/EBITDA
Profitability & Growth
PAVM
Metric
PFE
Profit Margin
Gross Margin
Operating Margin
Return on Equity
Return on Assets
Revenue Growth
EPS
Financial Health
PAVM
Metric
PFE
Debt-to-Equity
Lower = less leverage
Current Ratio
Above 1.0 is healthy
Beta
Lower = less volatile
Dividend Yield
Risk Comparison
PAVM
What Could Go Wrong
PAVmed Inc. faces immediate and critical financial risk with only $6.5 million in cash against quarterly operating expenses of $8.1 million as of Q1 2026. Failure to secure substantial new funding for...
Red Flags
- 🚩PAVmed Inc. consolidated cash balance of $6.5 million as of Q1 2026 vs. $8.1 million in quarterly op...
- 🚩Persistent high cash burn rate at the parent company without meaningful offsetting revenue generatio...
- 🚩High likelihood of significant future shareholder dilution for PAVmed Inc. common stock, given ongoi...
PFE
What Could Go Wrong
The biggest risk for Pfizer is the ongoing and accelerated erosion of revenue from key patent expirations and declining COVID-related product sales (Paxlovid/Comirnaty). If the pipeline of new product...
Red Flags
- 🚩Adjusted EPS declined -18% YoY in Q1 2026 despite revenue beat, indicating continued margin pressure...
- 🚩High reliance on successful pipeline execution to offset significant revenue declines from mature pr...
- 🚩Market Cap ($146.42B) requires an unrealistic 10x growth to over $1.4 trillion in 3-5 years, a scale...
Competitive Moat
PAVM
Rating
🛡️ None
Trend
📈 Expanding
PFE
Rating
🛡️ Wide
Trend
➡️ Stable
Investment Thesis
If PAVmed Inc. successfully secures near-term financing for its parent operations (e.g., $30M+ by Q3 2026) and Lucid Diagnostics significantly accelerates EsoGuard commercialization (e.g., reaching $5M+ quarterly revenue by Q4 2026 with expanding reimbursement) alongside Veris Health achieving FDA 510(k) clearance in late 2026, then the combined entity could see its market capitalization re-rate s...
Full PAVM AnalysisIf Pfizer's non-COVID product portfolio (e.g., Vyndaqel, Eliquis, newly launched oncology/rare disease drugs) continues to deliver mid-single-digit operational growth (above +5% YoY) and its late-stage pipeline yields 2-3 significant approvals (>$500M potential) over the next 18-24 months, then it could stabilize revenue around its $60B guidance range and see a modest re-rating to a 12-13x forward...
Full PFE AnalysisPrice Targets & Strategy
Price Targets & Entry/Exit Strategy
Sign up free to unlock the full comparison
Growth Catalysts
Growth Catalysts Comparison
Sign up free to unlock the full comparison
Market Sentiment
Market Sentiment Analysis
Sign up free to unlock the full comparison
The Deep Dive
PAVmed Inc. remains an extremely speculative investment. While Lucid Diagnostics (a subsidiary) shows nascent commercial progress with $1.3M in Q1 2026 EsoGuard revenue and 3,177 tests processed, PAVmed Inc.'s consolidated financial health is critically weak. The Q1 2026 report reveals only $6.5 million in cash and equivalents against $8.1 million in quarterly operating expenses, implying a cash runway of less than one quarter. This immediate liquidity concern for the parent company, coupled wit...
Full PAVM AnalysisPfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and Comirnaty contracts offer stability, but these are incremental gains for a company of Pfizer's scale....
Full PFE AnalysisWant More Comparisons?
Run any stock through our deep value analyzer.
Not Financial Advice
This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.